Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric dose-ranging study of cell-derived monovalent H1N1 swine-origin influenza vaccine formulations
2009-013640-37Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cell-derived monovalent H1N1 swine-origin influenza vaccine in influenza pandemic (2 arms), sponsored by Novartis. Primary endpoints: Primary immunogenicity endpoint and Safety and tolerability. Started Jul 2009; status: completed.
02
Drugs
cell-derived monovalent H1N1 swine-origin influenza vaccine
03
Conditions
influenza pandemic
Beyond the preview
Go deeper on 2009-013640-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013640-37.